In the last years, functional imaging has given a significant contribution to the clinical decision-making of biochemically relapsed prostate cancer (PCa). Hereby, we present a prospective study aiming to validate the role of [18F]Fluoro-Methyl Choline ([18F]FMCH) PET/CT in the selection of PCa patients suitable for stereotactic body radiotherapy (SBRT).
[18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer
Paiar F.;Erba P. A.Ultimo
2019-01-01
Abstract
In the last years, functional imaging has given a significant contribution to the clinical decision-making of biochemically relapsed prostate cancer (PCa). Hereby, we present a prospective study aiming to validate the role of [18F]Fluoro-Methyl Choline ([18F]FMCH) PET/CT in the selection of PCa patients suitable for stereotactic body radiotherapy (SBRT).File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Pasqualetti et al. EJNMMI 2019 [18F]Fluorocholine PET:CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer.pdf
accesso aperto
Descrizione: pdf
Tipologia:
Versione finale editoriale
Licenza:
Creative commons
Dimensione
286.5 kB
Formato
Adobe PDF
|
286.5 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
